Optimizing Patient Outcomes in Pancreatic Cancer With Al B. Benson, MD, FACP, FASCO is organized by i3 Health. Release: August 20, 2020 Expiration: August 19, 2021 Accreditation: Physicians: i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Description: With 5-year survival rates of only 37% for local disease, 12% for regional disease, and 3% for distant disease, pancreatic cancer is one of the most aggressive forms of cancer and one of the most challenging to treat. Despite the development of novel treatment approaches, therapeutic options remain limited. In this episode of Oncology Data Advisor, Al B. Benson, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and Associate Director for Cooperative Groups at Northwestern’s Robert H. Lurie Comprehensive Cancer Center, joins i3 Health for a discussion that covers recent developments in genomic testing and targeted therapies, supportive care measures that can optimize quality of life, and strategies that members of the cancer care team can utilize to improve the outcomes of their patients with pancreatic cancer. Learning Objectives: Upon completion of this activity, participants should be able to: • Identify the role that biomarkers can play in predicting therapeutic efficacy and developing tailored approaches to treatment • Develop effective multidisciplinary approaches that can be used to enhance pancreatic cancer treatment and supportive care https://www.i3health.com/oda-pancreatic Faculty: Al B. Benson, MD, FACP, FASCO, Professor of Medicine, Northwestern University Feinberg School of Medicine

Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD is organized by i3 Health. Release: September 18, 2020 Expiration: September 17, 2021 Accreditation: Physicians: i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Physician Assistants: American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program. Description: An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (BTK) inhibitor and chimeric antigen receptor (CAR) T-cell therapies, the management of adverse events associated with these treatments, updates on ongoing research, and advice for clinicians as they seek to optimize outcomes for patients with MCL. Learning Objectives: Upon completion of this activity, participants should be able to: • Assess efficacy and safety of novel BTK inhibitor therapy for MCL • Assess efficacy and safety of CAR T-cell therapy for MCL Faculty: Gilles Salles, MD, PhD Chief of the Lymphoma Service Memorial Sloan Kettering Cancer Center